Other OTC - Delayed Quote USD

Roche Holding AG (RHHBY)

30.25 +0.23 (+0.77%)
At close: April 26 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for RHHBY

Recent News: RHHBY

View More
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Zacks 3 days ago

UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Reuters 3 days ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
GlobeNewswire 3 days ago
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Zacks 8 days ago
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks 8 days ago
Roche wins FDA OK for Alecensa in early lung cancer

Roche wins FDA OK for Alecensa in early lung cancer
BioPharma Dive 8 days ago
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
GlobeNewswire 8 days ago
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Business Wire 9 days ago
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
Business Wire 10 days ago
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
GlobeNewswire 10 days ago
Adaptimmune (ADAP) Down on End of Collaboration With Roche

Adaptimmune (ADAP) Down on End of Collaboration With Roche
Zacks 12 days ago
Roche reports survival data for new dual-acting lymphoma drug

Roche reports survival data for new dual-acting lymphoma drug
BioPharma Dive 12 days ago
View More

Related Tickers

SNY Sanofi
49.13
-0.47%
 
NVS Novartis AG
97.44
-1.64%
 
GSK GSK plc
41.11
+0.49%
 
BAYRY Bayer Aktiengesellschaft
7.39
+1.65%
 
AZN AstraZeneca PLC
75.17
+0.19%
 
BMY Bristol-Myers Squibb Company
44.85
+0.34%
 
GILD Gilead Sciences, Inc.
65.42
+0.23%
 
AMGN Amgen Inc.
269.98
+0.22%
 
BIIB Biogen Inc.
208.90
+3.18%
 
OGN Organon & Co.
18.55
+0.71%